definiens: ) combined with the 1018 ISS ( as defined in the License Agreement ) in the Hep B Field ( as defined in the License Agreement ) ; and WHEREAS, [COMPANY] desires to use the Hepatitis B Surface Antigen, along with the 1018 ISS together with [COMPANY] 's fill and finish capabilities to sell Licensed Vaccines or Product ( as defined herein ) ; and WHEREAS, until such time that the process and formulation technology transfer from Dynavax to [COMPANY] is completed, Dynavax shall supply [COMPANY] and [COMPANY] shall purchase, its requirements for Licensed Vaccines or Products ( solely for use in Clinical Trials ( as defined in the License Agreeme nt ) ), [ subject to Dynavax 's current estimated theoretical maximum capacity limitation s ( which are subject to change in the future ) of approximately ( i ) 96 grams ( i.e., at theoretica l capacity, three million, one hundred thousand ( 3,100,000 ) Doses ( as defined herein ) ) annually of Hepatitis B Surface Antigen when Manufacturing ( as defined herein ) is occurring in the Pilot Facility, and Oi ) 300 grams ( i.e., at theoretical capacity, ten million ( 10,000,000 ) Doses ) annually of Hepatitis B Surface Antigen as Manufacturing is planned to occur in the Facility ( as defined herein ) and the current fill and finish capacity limitations of Dynavax 's Third Party contractors ] ; and WHEREAS, [COMPANY] wishes to engage Dynavax to Manufacture ( as defined herein ) on II = CERTAIN CONFIIlENTI AL INFORMATION CONTAINt : l ) IN TillS nOCtJM[!\'T, MARKED BY BRACKETS, IS FlLEn WITH TIlE SECURITIES AND EXCIIANGE COMMISS ION PURSUAN T TO RULE 24B·2 OF TlU : SECtJRITIES EXCIlt\!\ ' GE ACT OF 1934, AS A,\U : NDED